Executive Director, Antibody discovery & engineering

Lead the early-stage discovery strategy for the company's macromolecular drugs, including but not limited to high-throughput monoclonal antibodies (mAbs), differentiated bi-/multi-specific antibodies, next-generation ADCs, and fusion proteins. Formulate a comprehensive mid-to-long-term R&D pipeline strategy, spanning from target screening and validation to preclinical candidate (PCC) selection.Responsible for building and scaling antibody engineering core platforms (such as phage/mammalian display, single B-cell screening, affinity maturation, Fc engineering, humanization, and early druggability assessment). Proactively introduce cutting-edge technologies, such as AI-assisted antibody design (computational design), to enhance molecule discovery success rates and druggability.Lead cross-disciplinary teams (molecular biology, immunology, structural biology, CMC, pharmacology, and efficacy) to overcome R&D bottlenecks, ensuring efficient project progression against key milestones. Interface closely with the upstream Scientific Advisory Board (SAB) and downstream preclinical/translational medicine teams to ensure high-quality IND submission packages that strictly comply with NMPA, FDA, and EMA regulatory requirements.Provide robust technical due diligence support to empower the BD team in facilitating core asset in-licensing/out-licensing or strategic collaborations. Cultivate and maintain partnerships with top global research institutions, CRO vendors, and clinical experts to elevate the company's industry reputation in early-stage biologics discovery.Responsible for the organizational structure optimization, core talent cultivation, and performance incentive design of the biologics discovery department, building a highly self-driven and globally-minded team of scientists.